Herausgeber: Interdisziplinäre Arbeitsgruppe Hodentumoren
1. Bamberg M, Schmoll H-J, Weißbach L, Beyer J, Bokemeyer C, Harstrick A, Höltl W, Souchon R, Vogler H (1997) Interdisziplinäre Konsensus-Konferenz zur "Diagnostik und Therapie von Hodentumoren". Strahlenther Onkol 173, 397-406
2. Schmoll H-J, Bamberg M, Weißbach L (1997) Interdisziplinäre Konsensus-Konferenz zur Diagnostik und Therapie von Hodentumoren. Onkologie 20, 164-170
3. Deutsche Krebsgesellschaft e.V. (1995) Qualitätssicherung in der Onkologie. In: Enghofer E, Winkler R (Hrsg.) Grundlagen und Definition. Zuckschwerdt, München
4. Woolf SH (1992) Practice guidelines, a new reality in medicine II. Methods of developing guidelines. Arch Intern Med 152, 946-952
5. Ärztliche Zentralstelle Qualitätssicherung (1998) Checkliste "Methodische Qualität von Leitlinien" auf der Grundlage der "Beurteilungskriterien für Leitlinien der Bundesärztekammer und der Kassenärztlichen Bundesvereinigung". Dt Ärztebl 95 (Heft 41) A-2576-2578
6. Galandi D, Antes G (1999) Die Cochrane Collaboration. Das Krankenhaus 91 (8), 517-521
7. Ollenschläger G, Schott G (1999) Leitlinien und Evidenz-basierte Medizin in Deutschland. Onkologe 5, 826-829
8. Dieckmann KP, Loy V, Büttner P (1993) Prevalence of bilateral testicular germ cell tumors and early detection based on contralateral testicular intra-epithelial neoplasia. Brit J Urol 71, 340–345
9. Erpenbach K, Derschum W, Reis M (1997) Ergebnisse einer engmaschigen Hodentumornachsorge. Urologe A 29, 102–107
10. Osterlind A, Berthelsen JG, Abilgaard N, Hanssen SO, Hjalgrim H, Johansen B, Munck-Hansen J, Rasmussen LH (1991) Risk of bilateral testicular germ cell tumors in Denmark: 1960 – 1984. J Natl Cancer Inst 83, 1391-1395
11. von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen BL, Christophersen IS, Hald T, Jacobsen GK, Berthelsen JG, Skakkebaek NE (1986) Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 293, 1398-1401
12. Moller H, Prener A, Skakkebaek NE (1996) Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy and genital malformations: case-control studies in Denmark. Cancer Causes Control 7, 264-274
13. Prener A, Hsieh CC, Engholm G, Trichopoulos D, Jensen OM (1992) Birth order and risk of testicular cancer. Cancer Causes Control 3, 265–272
14. Tollerud DJ, Blattner WA, Fraser MC, Brown LM, Pottern L, Shapiro E, Kirkemo A, Shawker TH, Javadpour N, O’Connell K, Stutzman RE, Fraumeni JF (1985) Familial testicular cancer and urogenital developmental anomalies. Cancer 55, 1849-1854
15. Pinczowski D, McLaughlin JK, Lackgren G, Adami HO, Persson I (1991) Occurrence of testicular cancer in patients operated on for cryptorchidism and inguinal hernia. J Urol 146, 1291-1294
16. Swerdlow AJ, De Stavola BL, Swanwick MA, Mangtani P, Maconochie NE (1999) Risk factor for testicular cancer: a case control study in twins. Br J Cancer 80, 1098-1102
17. Dieckmann KP, Pichlmeier U (1997) The prevalence of familial testicular cancer. Cancer 80, 1954-1960
18. Forman D, Oliver RTD, Marsh SGE, Moses JH, Bodmer JG, Chilvers CED, Pike MC (1992) Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Brit J Cancer 65, 255-262
19. Heidenreich A für die Interdisziplinäre Arbeitsgruppe Hodentumoren (1999) Klinische und biologische Charakteristika familiärer, bilateraler und sporadischer Keimzelltumoren des Hodens. Urologe A 38 (Suppl 1), 65, (abstract 9.1)
20. Westergaard T, Olsen JH, Frisch M, Kroman N, Nielsen JW, Melbye M (1996) Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population based study. Int J Cancer 66, 627-631
21.Nichols CR (1998) Testicular cancer. Curr Probl Cancer 22, 187-274
22. Albers P (1997) Diagnostik und Therapie von Hodentumoren. Urologe A 36, 387-396
23. Bassetto MA, Pasini F, Franceschi T, Mustacchi, Cetto GL (1995) Extragonadal germ cell tumour: a clinical study. Anticancer Res 15, 2751-2754
24. Casella R, Rochlitz C, Sauter G, Gasser TC (1999) "Burned out" testicular tumour: a rare form of germ cell neoplasias. Schweiz Med Wochenschr 129, 235-240
25. de Takats PG, Jones SR, Penn R, Cullen, MH (1996) Alpha-foetoprotein heterogeneity: what is its value in managing patients with germ cell tumours? Clin Oncol (R Coll Radiol) 8, 323-326
26. Dueland S, Stenwig AE, Heilo A, Hoie J, Ous S, Fossa SD (1998) Treatment and outcome of patients with extragonadal germ cell tumours – the Norwegian Radium Hospital‘s experience 1979-94. Br J Cancer 77, 329-335
27. Hartman M, Pottek T, Bussar-Maatz R, Weissbach L (1997) Elevated human chorionic gonadotropin concentrations in the testicular vein and in peripheral venous blood in seminome patients. An analysis of various parameters. Eur Urol 31, 408-413
28. van de Gaer P, Verstraete H, De Wever I, Oyen R (1998) Primary retroperitoneal extragonadal germ cell tumour. J Belge Radiol 81, 221-222
29. Leibovitch I, Little JS, Foster RS, Rowland RG, Bihrle R, Donohue JP (1996) Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. J Urol 155, 952-954
30. Simmonds PD, Mead GM, Lee AHS, Theaker JM, Dewbury K, Smart CJ (1995) Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Cancer 75, 1018-1024
31. Capelouto CC, Clark PE, Ransil BJ, Loughlin KR (1995) A review of scrotal violation in testicular cancer: Is adjuvant local therapy necessary? J Urol 153, 981-985
32. Harding M, Paul J, Kaye SB (1995) Does delayed diagnosis or scrotal incision affect outcome for men with nonseminomatous germ cell tumors? Brit J Urol 76, 491-494
33. Leibovitch I, Baniel J, Foster RS, Donohue JP (1995) The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer. J Urol 154, 935-939
34. Heidenreich A, Vorreuther R, Braun M, Engelmann UH (1995) Ist eine schnellschnittgesteuerte Therapieplanung bei testikulären Raumforderungen sinnvoll? Urologe A 34 (Suppl.), 113 (abstract P11.4)
35. Robertson GS (1995) Radical orchiectomy and benign testicular conditions. Br J Surg 82, 342-345
36. Tokuc R, Sakr W, Pontes JE, Haas GP (1992) Accuracy of frozen section examination of testicular tumors. Urology 40, 521-516
37. Heidenreich A, Bonfig R, Derschum W, Vietsch HV, Wilbert DM (1995) A conservative approach to bilateral testicular germ cell tumors. J Urol 153, 10-13
38. Heidenreich A, Höhlt W, Albrecht W, Pont J, Engelmann UH (1997) Testis-preserving surgery in bilateral testicular germ cell tumours. Brit J Urol 79, 253-257
39. Weissbach L (1995) Organ preserving surgery of malignant germ cell tumors. J Urol 153, 90-93
40. Dieckmann KP, Loy V (1996) Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 14, 3126–3132
41. Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC, Roberts JT, Stenning SP (1998) Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol 160, 1353-1357
42. Giwercman A, Cantell L, Marks A (1991) Placental-alkaline phosphatase as a marker of carcinoma-in-situ of the testis. Comparison with monoclonal antibodies M2A and 43-9F. APMIS 99, 586-594
43. Giwercman A, Andrews PW, Jorgensen P, Müller J, Groern N, Skakkebaek NE (1993) Immunohistochemical expression of embryonal marker TRA-1-60 in carcinoma in situ and germ cell tumors of the testis. Cancer 72, 1308-1314
44. Mostofi FK, Sesterhenn IA (1998) Histological typing of testis tumours. 2nd ed. WHO International Histological Classification of Tumours. Springer, Berlin Heidelberg New York Tokyo
45. Dudeck J, Wagner G, Grundmann E, Hermanek P (1999) Qualitätssicherung in der Onkologie: Basisdokumentation für Tumorkranke. Prinzipien und Verschlüsselungsanweisungen für Klinik und Praxis. Zuckschwerdt, München Bern Wien New York
46. Wagner G (1991) Tumorlokalisationsschlüssel 4. Auflage. Erweiterte Übersetzung der International Classification of Diseases for Oncology (ICD-O) 2. Auflage. ADT Tumordokumentation in Klinik und Praxis. Band 1. Springer, Berlin Heidelberg New York Tokyo
47. UICC (1997) TNM-Klassifikation maligner Tumoren. 5. Aufl. (Hrsg.: Wittekind Ch, Wagner G). Springer Berlin Heidelberg New York
47. UICC (1997) TNM-Klassifikation maligner Tumoren. 5. Aufl. (Hrsg.: Wittekind Ch, Wagner G). Springer Berlin Heidelberg New York
48. Jensen K, Abel U (1999) Methodik diagnostischer Validierungsstudien. Med Klin 94, 522-528
49. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JHP, Bossuyt PMM (1999) Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282, 1061-1066
50. Gospodarowicz MK, Sturgeon JFG, Jewett MAS (1998) Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. Semin Oncol 25, 160-173
51. Krug B, Heidenreich A, Dietlein M, Lackner (1999) Lymphknotenstaging maligner testikulärer Keimzelltumoren. Fortschr Röntgenstr 171, 87-94
52. Lashley D, Lowe B (1998) A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am 25, 405-423
53. Leibovitch I, Foster RS, Kopecky KK, Albers P, Ulbright TM, Donohue JP (1998) Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: A combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 16, 261-268
54. White PM, Howard GC, Best JJ, Wright AR (1997) The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours. Clin Radiol 52, 124-129
55. White PM, Adamson DJA, Howard GCW, Wright AR (1999) Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol 54, 207-211
56. Bundesärztekammer (1992) Leitlinien der Bundesärztekammer zur Qualitätssicherung in der Computertomographie. Dt Ärztebl 89, 3-11
57. Bundesausschuß der Ärzte und Krankenkassen (1997) Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über Kriterien zur Qualitätsbeurteilung in der radiologischen Diagnostik gemäß § 136 SGB V in der Fassung vom 17. Juni 1992 (veröffentlicht im Bundesanzeiger Nr. 183b vom 29, September 1992), zuletzt geändert am 17. Dezember 1996 (veröffentlicht im Bundesanzeiger Nr. 49 vom 12. März 1997). Dt Ärztebl 94, C-581-588
58. Fernandez EB, Moul JW, Foley JP, Colon E, McLeod DG (1994) Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology 44, 548-552
59. Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW (1998) Prognostic factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83, 1002-1011
60. See WA, Hoxie L (1993) Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. J Urol 150, 874-878
61. Leibovitch I, Foster RS, Kopecky KK, Donohue JP (1995) Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell tumor using size criteria of retroperitoneal lymph nodes. J Urol 154, 1759-1763
62. McLeod DG, Weiss RB, Stablein DM, Muggia FM, Paulson DF, Ellis JH, Spaulding JT, Donohue JP (1991): Testicular Cancer Intergroup Study: Staging relationships and outcome in early stage testicular cancer: A report from the Testicular Cancer Intergroup Study. J Urol 145, 1178-1183
63. Weißbach L, Bussar-Maatz R (1997) Hodentumoren. In: Rübben H (Hrsg.): Uroonkologie. Springer, Berlin Heidelberg New York, pp 433-533
64. Tschammler A, Knitter J, Wittenberg G, Krahe Th, Hahn D (1995) Quantifizierung der Lymphknotenperfusion mittels farbkodierter Duplexsonographie. Fortschr Röntgenstr 163, 203-209
65. Bellin M, Roy C, Kinkel K, Thoumas D, Zaim S, Vanel D, Tuchmann C, Richard F, Jacqmin D, Delcourt A, Challier E, Lebret T, Cluzel P (1998) Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - initial clinical experience. Radiology 207, 799-808
66. Hogeboom WR, Hoekstra HJ, Mooyart EL, Sleijfert DT, Schraffordt Koops H (1993) Magnetic resonance imaging of retroperitoneal lymph node metastases of non-seminomatous germ cell tumors of the testis. Eur J Surg Oncol 19, 429-437
67. Krug B (1997) Becken. In: Heindel W, Kugel H, Lackner K (Hrsg.): Rationelle MR-Untersuchungstechniken. Thieme Stuttgart 1997, pp 52-55
68. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Müller SC (1999) Positron emission tomography in the clinical staging of patients with stage I and II germ cell tumors. Urology 53, 808-811
69. Cremerius U, Wildberger JE, Borchers H, Zimny M, Jakse G, Gunther RW, Buell U (1999) Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? – Results of a study of 50 patients. Urology 54, 900-904
70. de Wit M, Bokemeyer C, Hartmann D, Abenhardt W, Schmeller N, Jakse G, Büll U, Claussen M, Hossfeld DK, Bares R (1997) Germ cell tumor (GCT): Staging and therapy control with (18)FDG-PET. First results of German multicenter trial. Eur J Cancer 33 (Suppl. 8), 159
71. Hoh CK, Seltzer MA, Franklin J, de Kernison JB, Phelbs ME, Belldegrun A (1998) Positron emissions tomography in urological oncology. J Urol 159, 347-356
72. Müller-Mattheis V, Reinhardt M, Gerharz CD, Fürst G, Vosberg H, Müller-Gärtner HW, Ackermann (1998) Die Positronenemissionstomographie mit (18F)-2-fluoro-2-deoxy-D-glukose (18FDG-PET) bei der Diagnostik retroperitonealer Lymphknotenmetastasen von Hodentumoren. Urologe A 37, 609-620
73. Reske SN (1998) Positronen-Emissions-Tomographie in der Onkologie. Dt Ärztebl 95, C-1370-1372
74. Reske SN, Bares R, Büll U, Guhlmann A, Moser E, Wannenmacher MF (1996) Klinische Wertigkeit der Positronen-Emissions-Tomographie (PET) bei onkologischen Fragestellungen: Ergebnisse einer interdisziplinären Konsensuskonferenz. Nuklearmedizin 35, 42-52
75. Weber WA, Avril N, Schwaiger M (1999) Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 175, 356-376
76. Wilson CB, Young HE, Ott RJ, Flower MA, Cronin BF, Pratt BE, McCready VR, Horwich A (1995) Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 22, 508-513
77. International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) The International Germ Cell Consensus Classification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15, 594-603
78. Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ (1997) Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 15, 1449-1454
79. Fossa SD, Bokemeyer C, Gerl A, Culine S, Jones WG, Mead GM, Germa-Lluch JR, Pont J, Schmoll HJ, Tjulandin S (1999) Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 85, 988-97
80. Schmoll H-J (1999) Maligne Keimzelltumoren des Mannes. In: Schmoll H-J, Höffken K, Possinger K (Hrsg.): Kompendium Internistische Onkologie Teil 2, 3. Auflage, Springer Heidelberg, 1659-1732
81. Mead GM (1995) International consensus prognostic classification for metastatic germ cell tumours treated with platinum based chemotherapy: Final report of the International Germ Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol 14, 235 (abstract 615)
82. Fossa SD, Dahl AA, Haaland CF (1999) Health-related quality of life in patients treated for testicular cancer. Curr Opinion Urol 9, 425-429
83. Kliesch S, Behre HM, Jürgens H, Nieschlag E (1996) Cryopreservation of semen from adolescent patients with malignancies. Med Ped Oncol 26, 20-27
84. Kliesch S, Kamischke A, Nieschlag E (1997) Cryopreservation of sperm. In: Nieschlag E, Behre HM (eds): Andrology – Male reproductive health and dysfunction. Springer, Berlin New York, pp 349-358
85. Petersen PM, Skakkebaek NE, Giwercman A (1998) Gonadal function in men with testicular cancer: Biological and clinical aspects. APMIS 106, 24-36
86. Dieckmann KP, Loy V (1993) Paternity in a patient with testicular seminoma and contralateral testicular intraepithelial neoplasia. Int J Androl 16, 143-146
87. Giwercman A, von der Maase H, Rorth M, Skakkebaek NE (1993) Semen quality in testicular tumour and CIS in the contralateral testis. Lancet 341, 384-385
88. Giwercman A, von der Maase H, Rorth M, Skakkebaek NE (1994) Current concepts of radiation treatment of carcinoma in situ of the testis. World J Urol 12, 125-130
89. Heidenreich A, Vorreuther R, Neubauer S, Zumbe J, Engelmann UH (1997) Paternity in patients with bilateral testicular germ cell tumors. Eur Urol 31, 246-248
90. Kliesch S, Bergmann M, Hertle L, Nieschlag E, Behre HM (1997) Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. Hum Reprod 12, 2830-2835
91. Nieschlag E, Behre HM (1997) Therapie mit Testosteron. In: Nieschlag E, Behre HM (Hrsg.): Andrologie - Grundlagen und Klinik der reproduktiven Gesundheit des Mannes. Springer, Berlin New York, pp 316-329
92. Nieschlag E, Behre HM (1999) Pharmacology and clinical use of testosterone. In: Nieschlag E, Behre HM (eds): Testosterone – action, deficiency, substitution. Springer Verlag, Berlin New York, pp 92-114
59. Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW (1998) Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83, 1002-1011
93. von der Maase H (1999) Prognostic factors for stage I seminoma. UICC-Symposium on Testicular Cancer, Tübingen, Abstractband, 21-22
94. Warde P, von der Maase H, Horwich A, Gospodarowicz M, Panzarella T, Specht L (1998) Prognostic factors for relapse in stage I seminoma managed by surveillance. Proc Am Soc Clin Oncol 17, 309a (abstr. 1188)
95. Warde P, Gospodarowicz MK, Banerjee D, Panzarella T, Sugar L, Catton CN, Sturgeon JFG, Moore M, Jewett MAS (1997) Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 157, 1705-1710
96. Weissbach L, Bussar-Maatz R, Löhrs U, Schubert GE, Mann K, Hartmann M, Dieckmann KP, Fassbinder (1999) Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study. Eur Urol 36, 601-608
97. Horwich A, Alsanjari N, A’Hearn R, Nicholls J, Dearnaley DP, Fisher C (1992) Surveillance following orchiectomy for stage I testicular seminoma. Br J Cancer 65, 775–778
98. Böhlen D, Borner M, Sonntag RW, Fey MF, Studer UE (1999) Longterm results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161, 1148-1152
99. Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J, Nilsson S, Daehlin L, Tornblom M, Smaland R, Starkhammar H, Abramsson L, Wist E, Raabe N, Edekling T, Cavallin-Stahl E (1997) Risk-adapted treatment of clinical stage I non-seminoma testis cancer. Eur J Cancer 33, 1038-1044
100. Kratzik Ch, Höltl W, Albrecht W, Pont J, Zielinski CH, Breindl E, Pummer K, Hubmer G, Marberger M (1996) Risk adapted management for NSGCT stage 1 - long-term results of a multicenter study. J Urol 157, 547A
101. Ondrus D, Matoska J, Belan V, Kausitz J, Goncalves F, Hornak M (1998) Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 33, 562-566
102. Pont J, Holtl W, Kosak D, Machacek E, Kienzer H, Julcher H, Honetz N (1990) Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. J Clin Oncol 8, 16-19
103. Albers P, Ulbright TM, Albers J, Miller GA, Orazi A, Crabtree WN, Baniel J, Reister T, Sidner RA, Foster RS, Donohue JP (1996) Tumor proliferative activity is predictive of pathological stage in clinical stage A non-seminomatous testicular germ cell tumors. J Urol 155, 579-586
104. Madej G, Pawinski A (1991) Risk-related adjuvant chemotherapy for stage I non-seminoma of the testis. Clin Oncol 3, 270-272
105. Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, Cook PA (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 10, 1762-1768
106. Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HAT, Bosl G (1998) Clinical stage I testis cancer: longterm outcome of patients on surveillance. J Urol 159, 855-858
107. Albers P, Bierhoff E, Neu D, Fimmers R, Wernert N, Müller SC (1997) MIB-1 immunohistochemistry predicts patients at low risk of metastasis in clinical stage I non-seminomatous testicular germ cell tumors. Cancer 79, 1710-1716
108. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA (1994) Percentage of embryonal carcinoma and vascular invasion predict pathologic stage in clinical stage I non-seminomatous testicular cancer. Cancer Research 54, 1-3
109. de Riese WT, Albers P, Walker EB, Ulbright TM, Crabtree WN, Reister T, Foster RS, Donohue JP (1994) Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors. Cancer 74, 1335-1341
110. Heidenreich A, Schenkman NS, Sesterhenn IA, Mostofi FK, McCarthy WF, Heidenreich B, Mould JW (1997) Immunohistochemical expression of Ki-67 to predict lymph node involvement in clincial stage I nonseminomatous germ cell tumors. J Urol 158, 620-625
111. Nicolai N, Pizzocaro G (1995) A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: a 10-year follow up. J Urol 154, 1045-1049
112. Sweeney CJ, Hermans BP, Heilman DK, Foster RS, Donohue JP, Einhorn (2000) Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. J Clin Oncol 18, 358-362
113. Javadpour N, Canning DA, O´Connell KJ, Young JD (1986) Predictors of recurrent clinical stage I nonseminomatous testicular cancer. A prospective clinicopathologic study. Urology 27, 508-511
114. Sesterhenn IA, Weiss RB, Mostofi FK, Stablein DM, Rowland RG, Falkson G, Rivkind SE, Vogelzang NJ (1992) Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 10, 69-78
77. International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15, 594-603
81. Mead GM (1995) International consensus prognostic classification for metastatic germ cell tumours treated with platinum based chemotherapy: Final report of the International Germ Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol 14, 235 (abstract 615)
115. Beyer J, Schmoll HJ (1998) Prognosefaktoren bei metastasierten seminomatösen und nichtseminomatösen Hodentumoren. Onkologe 4, 518-523
116. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJ, Cook PA (1999) Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80, 1392-1399
88. Giwercman A, von der Maase H, Rorth M, Skakkebaek NE (1994) Current concepts of radiation treatment of carcinoma in situ of the testis. World J Urol 12, 125-130
117. Skakkebaek NE, Berthelsen JG, Müller J (1982) Carcinoma in situ of the undescended testis. Urol Clin North Am 9, 377-385
118. Dieckmann KP, Besserer A, Loy V (1993) Low-dose radiation therapy for testicular intraepithelial neoplasia. J Cancer Res Clin Oncol 119, 355-359
119. Dieckmann KP, Loy V (1998) The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: the recent German experience. Apmis 106, 13-20
120. Christensen TB, Daugaard G, Geertsen PF, von der Maase H (1998) Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 9, 657-660
93. von der Maase H (1999) Prognostic factors for stage I seminoma. UICC-Symposium on Testicular Cancer, Tübingen, Abstractband, 21-22
94. Warde P, von der Maase H, Horwich A, Gospodarowicz M, Panzarella T, Specht L (1998) Prognostic factors for relapse in stage I seminoma managed by surveillance. Proc Am Soc Clin Oncol 17, 309a (abstr. 1188)
95. Warde P, Gospodarowicz MK, Banerjee D, Panzarella T, Sugar L, Catton CN, Sturgeon JFG, Moore M, Jewett MAS (1997) Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 157, 1705-1710
97. Horwich A, Alsanjari N, A’Hern R, Nicholls J, Dearnaley DP, Fisher C (1992) Surveillance following orchiectomy for stage I testicular seminoma. Br J Cancer 65, 775–778
121. von der Maase H, Warde P, Specht L, Horwich A, Gospodarowicz M, Panzarella T (1998) Prognostic factors for relapse following surveillance in seminoma stage I patients. Radiother Oncol 48 (Suppl. 1), 11 (abstract 42)
122. Warde PR, Gospodarowicz MK, Goodman PJ, Sturgeon JF, Jewett MA, Catton CN, Richmond H, Thomas G, Duncan W, Munro AJ (1993) Results of a policy of surveillance in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 27, 11-15
123. Warde P, Gospodarowicz MK, Panzarella T, Catton CN, Sturgeon JF, Moore M, Goodman P, Jewett MA (1995) Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 13, 2255-2262
124. Fossa SD, Horwich A, Russel JM, Roberts JT, Cullen MH, Hodsen NJ, Jones WG, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD, Reed NS, Widmer B, Stenning SP (1999) Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 17, 1146-1154
125. Bamberg M, Schmidberger H, Meisner C, Classen J, Souchon R, Weinknecht S, Schorcht J, Walter F, Engenhart-Cabillic R, Schulz U, Born H, Flink M (1999) Radiotherapy for stage I, IIA/B testicular seminoma. Int J Cancer 83, 823-827
126. Jones CU, Rosenthal SA, Chang GC, Andra EJ, Stickney DR, Russel AH, Wolkov HB, Linstadt DE, Banker FL, Leibenhaut MH (1998) Is pelvic RT necessary in the treatment of stage I testicular seminoma? Int J Radiat Oncol Biol Phys 42 (Suppl.1), 2117
127. Kiricuta IO, Sauer J, Bohndorf W (1996) Omission of the pelvic irradiation in stage I testicular seminoma: A study of postorchiectomy paraaortic radiotherapy. Int J Radiat Oncol Biol Phys 35, 293-298
128. Warde P, Jewett MAS (1998) Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 25, 425-433
129. Logue JP, Mobarek N, Read G (1998) Short fractionation para-aortic radiotherapy for stage I seminoma of the testis. Radiother Oncol 48 (Suppl. 1), 10
130. Dieckmann K-P, Brüggeboes B, Pichlmeier U, Küster J, Müllerleile U, Bartels H (2000) Adjuvant treatment of clinical stage I seminoma: Is one single course of carboplatin sufficient? Urology 55, 102-106
131. Mason M, Jones W (1997) Treatment of stage I seminoma: more choice, more dilemmas. Clin Oncol 9, 210-212
132. Oliver RTD, Ong J (1996) Seventeen years experience of phase I/II studies of single agent platinum compounds as alternatives to radiation for metastatic and stage I seminoma. Proc Am Soc Clin Oncol 15, 244 (abstract 613)
133. Krege S, Kalund G, Otto T, Goepel M, Rübben H (1997) Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol 31, 405-407
134. Dosman MA, Zagars GK (1993) Postorchiectomy radiotherapy for stages I and II testicular seminoma. Int J Radiat Oncol Biol Phys 26, 381-390
135. Zagars GK (1996) Management of stage I seminoma: radiotherapy. In Horwich A (ed): Testicular Cancer: investigation and management. Chapman & Hall, London, pp 99-106
136. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF, Boice JD (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89, 1429-1439
137. Travis L, Andersson M, Holowarty E, Van Leeuwen F, Bergfeldt K, Lynch C, Kohler B, Wiklund T, Curtis R, Storm H, Clarke E, Hall P, Pukkala E, Sturgeon J, Boice Jr, J, Gospodarowicz M, Sovall M, Gilbert E (1999) Risk of leukemia following radiotherapy and chemotherapy for testicular cancer. Proc Am Soc Clin Onc 18, 308a (abstract 1185)
138. Sternberg CN (1998) The management of stage I testis cancer. Urol Clin North Am 25, 435-449
139. von der Maase H, Specht L, Jacobsen GK, Jakobsen A, Madsen EL, Pedersen M, Rorth M, Schultz H (1993) Surveillance following orchiectomy for stage I seminoma of the testis. Eur J Cancer 29A, 1931-1934
140. Fossa SD, Moynihan C, Serbuti S (1996) Patients‘ and doctors‘ perception of long-term morbidity in patients with testicular cancer clinical stage I. Support Care Cancer 4, 118-128
31. Capelouto CC, Clark PE, Ransil BJ, Loughlin KR (1995) A review of scrotal violation in testicular cancer: Is adjuvant local therapy necessary? J Urol 153, 981-985
141. Schmidberger H, Bamberg M, Meisner C, Classen J, Winkler C, Hartmann M, Templin R, Wiegel T, Dornoff W, Ross D, Thiel H-J, Martini C, Haase W (1997) Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiol Oncol Biol Phys 39, 321-326
142. Bauman GS, Venkatesan VM, Ago CT, Radwan JS, Dar AR, Winquist EW (1998)
Postoperative radiotherapy for stage I/II seminoma: results of 212 patients. Int J Radiat Oncol Biol Phys 42, 313-317
143. Bayens YC, Helle PA, van Putten WLJ, Mali SPM (1992) Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study. Radiother Oncol 25, 97-102
144. Hültenschmidt B, Budach V, Genters K, Sack H (1996) Results of radiotherapy for 230 patients with stage I-II seminomas. Strahlenther Onkol 172, 186-192
145. Kellokumpu-Lehtinen P, Halme A (1990) Results of treatment in irradiated testicular seminoma patients. Radiother Oncol 18, 1-7
146. Lai PP, Bernstein MJ, Kim H, Perez CA, Wasserman TH, Kucik NA (1993) Radiation therapy for stage I and IIA testicular seminoma. Int J Radiat Oncol Bio Phys 28, 373-379
147. Lederman GS, Herman TS, Jochelson M, Silver BJ, Chaffey JT, Garnick MB, Richie J, Sheldon TA, Coleman CN (1989) Radiation therapy of seminoma: 17-year experience at the Joint Center for radiation therapy. Radiother Oncol 14, 203-208
148. Vallis KA, Howard GCW, Duncan W, Cornbleet MA, Kerr GR (1995) Radiotherapy for stage I and II testicular seminoma: results and morbidity in 238 patients. Brit J Radiol 68, 400-405
149. Warde P, Gospodarowicz M, Panzarella T, Catton C, Sturgeon J, Moore M, Jewett M (1998) Management of stage II seminoma. J Clin Oncol 16, 290-294
150. Whipple GL, Sagerman RH, van Rooy EM (1997) Long-term evaluation of postorchiectomy radiotherapy for stage II seminoma. Am J Clin Oncol (CCT) 20, 196-201
151. Kennedy CL, Hendry WF, Peckham MJ (1986) The significance of scrotal interference in stage I testicular cancer managed by orchiectomy and surveillance. Brit J Urol 58, 705-708
152. Thomas GM, Rider WD, Dembo AJ, Cummings BJ, Gospodarowicz M, Hawkins NV, Herman JG, Keen CW (1982) Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. Int J Radiat Oncol Biol Phys 8, 165-174
153. Zagars GK, Babaian RJ (1987) The role of radiation in stage II testicular seminoma. Int J Radiat Oncol Biol Phys 13, 162-170
58. Fernandez EB, Moul JW, Foley JP, Colon E, McLeod DG (1994) Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology 44, 548-552
99. Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J, Nilsson S, Daehlin L, Tornblom M, Smaland R, Starkhammar H, Abramsson L, Wist E, Raabe N, Edekling T, Cavallin-Stahl E (1997) Risk-adapted treatment of clinical stage I non-seminoma testis cancer. Eur J Cancer 33, 1038-1044
101. Ondrus D, Matoska J, Belan V, Kausitz J, Goncalves F, Hornak M (1998) Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 33, 562-566
105. Read G, Stenning SP, Cullen MH et al. (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 10, 1762-1768
110. Kratzik Ch, Höltl W, Albrecht W, Pont J, Zielinski CH, Breindl E, Pummer K, Hubmer G, Marberger M (1996) Risk adapted management for NSGCT stage 1 - long-term results of a multicenter study. J Urol 157, 547A
114. Sesterhenn IA, Weiss RB, Mostofi FK, Stablein DM, Rowland RG, Falkson G, Rivkind SE, Vogelzang NJ (1992) Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 10, 69-78
140. Fossa SD, Moynihan C, Serbuti S (1996) Patients‘ and doctors‘ perception of long-term morbidity in patients with testicular cancer clinical stage I. Support Care Cancer 4, 118-128
154. Pizzocaro G, Nicolai N, Salvioni R, Piva L, Faustini M, Zanoni F, Milani A (1992) Comparison between clinical and pathological staging in low stage nonseminomatous germ cell testicular tumors. J Urol 148, 76-79
155. Donohue JP, Thornhill JA, Foster RS, Rowland RS, Bihrle R (1993) Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965-1989): modifications of technique and impact on ejaculation. J Urol 149, 237-243
156. Sharir S, Foster RS, Jewett MAS, Sturgeon JFG, Moore M, Donohue JP (1996) Optimizing follow up for early stage nonseminomatous testicular cancer. J Urol 155 (Suppl.), 327a (abstract 67)
157. Weissbach L, Boedefeld EA, Horstmann-Dubral B, for Testicular Tumor Study Group Bonn (1990) Surgical treatment of stage-I non-seminomatous germ cell testis tumor. Eur Urol 17, 97-106
158. Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G (1990) Nervesparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 144, 287-292
159. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP (1994) Complications of primary retroperitoneal lymph node dissection. J Urol 152, 424-427
160. Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W (1996) Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14, 441-448
161. Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH, Harland SJ, Williams MV, Jakes R (1996) Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14, 1106-1113
162. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C (1999) Long term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer 80, 801-807
159. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP (1994) Complications of primary retroperitoneal lymph node dissection. J Urol 152, 424-427
163. Williams SD, Stablein DM, Einhorn LH et al. (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. New Engl J Med 317, 1433-1438
164. Weißbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L (2000) RPLND or primary chemotherapy in clinical stage IIA/B non-seminomatous germ cell tumors? – Results of a prospective multi-centre trial including quality of life assessment. Eur Urol (2000) in press
165. Donohue JP, Thornhill JA, Foster RS, Bihrle R, Rowland RG, Einhorn LH (1995) The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: The Indiana University experience (1965 to 1989). J Urol 153, 85-89
166. Kennedy BJ, Torkelson JL, Fraley EE (1994) Adjuvant chemotherapy for stage II nonseminomatous germ cell cancer of the testis. Cancer 73, 1485-1489
167. Jewitt MAS, Sturgeon JFG, Gospodarowicz MK et al. (1993) Comparison of the natural history of stage I nonseminoma and seminoma testis using the result of expectant management. J Urol 149, 308 A
168. de Bruin MJFM, Oosterhof GON, Debruyne FM (1993) Nerve-sparing retroperitoneal lymphadenectomy for low stage testicular cancer. Br J Urol 71, 336-339
169. Pont J, Albrecht W (1997) Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril 68, 1-5
170. Brennemann W, Stoffel-Wagner B, Herlmers A, Mezger J, Jäger N, Klingmüller D (1997) Gonadal function of patients treated with cisplatin based chemotherapy for germ
cell cancer. J Urol 158, 844-850
171. Pizzocaro G, Monfardini S (1994) No adjuvant chemotherapy in selected patients with pathological stage II nonseminomatous germ cell tumors of the testis. J Urol 131, 677-680
172. Weißbach L, Hartlapp JH (1991) Adjuvant chemotherapy of metastatic stage II non-seminomatous testis tumor. J Urol 146, 1285-1298
173. Kuczyk M, Machtens S, Stief C, Jonas U (1999) Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (GCT). Int J Cancer 83, 852-855
174. Horwich A, Stenning S (1994) Initial chemotherapy for stage II testicular nonseminoma. World J Urol 12, 148-150
175. Horwich A, Huddart R, Dearnaley D (1998) Markers and management of germ-cell tumours of the testis. Lancet 352 (9139), 1535-1538
176. Logothetis CJ, Samuels ML, Selig DE, Johnson DE, Swanson DA, von Eschenbach AC (1985) Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. J Urol 134, 1127-1130
177. Peckham MJ, Hendry WF (1985) Clinical stage II non-seminatous germ cell testicular tumors. Results of management by primary chemotherapy. Br J Urol 57, 763-768
178. Aass N, Kaasa S, Lund E, Kaalhus O, Heier MS, Fossa SD (1990) Long term somatic side-effects and morbidity in testicular cancer patients. Brit J Cancer 61, 151-155
179. Boyer MJ, Cox K, Tattersall MH et al. (1997) Active surveillance after orchiectomy for nonseminomatous testicular germ cell tumors: late relapse may occur. Urology 50, 588-592
180. Stuart NSA, Woodroffe CM, Grundy R, Cullen MH (1990) Long-term toxicity of chemotherapy for testicular cancer-the cost of cure. Br J Cancer 61, 479-484
181. Bokemeyer C, Schmoll H-J (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11, 1703-1709
77. International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) The International Germ Cell Consensus Classification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15, 594-603
81. Mead GM (1995) International consensus prognostic classification for metastatic germ cell tumours treated with platinum based chemotherapy: final report of the International Germ Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol 14, 235 (abstract 615)
182. de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, Rea LA, Collette L, Sylvester R (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15, 1837-1843
183. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15, 1844-1852
184. Bokemeyer C, Kuczyk MA, Köhne H, Einsele H, Kynast B, Schmoll HJ (1996) Hematopoetic growth factors and treatment of testicular cancer: biological interactions, routine use and dose intensive chemotherapy. Ann Hematol 72, 1-9
185. Fossa SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I, van Groeningen CJ, de Mulder PH; Stenning S; Lallemand E; de Prijck L; Collette L (1998) Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16, 716-724
186. de Wit R, Stoter G, Sleijfer DT, NeijtJP, ten Bokkel Huinink WW, de Prijck L, Collette L, Sylvester R (1998) Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 78, 828-832
187. de Wit R, Louwerens M, de Mulder PH, Verweij J, Rodenhuis S, Schornagel J (1999) Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer 83, 831-833
188. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16, 1287-1293
189. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 17, 3450-3456
190. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V (1997) High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15, 2546-52
78. Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ (1997) Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 15, 1449-1454
79. Fossa SD, Bokemeyer C, Gerl A, Culine S, Jones WG, Mead GM, Germa-Lluch JR, Pont J, Schmoll HJ, Tjulandin S (1999) Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 85, 988-97
191. Spears WT, Morphis JG, Lester SG, Williams SD, Einhorn LH (1991) Brain metastases and testicular tumors: long-term survival. Int J Radiat Oncol Biol Phys 22, 17-22
77. International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) The International Germ Cell Consensus Classification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15, 594-603
190. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V (1997) High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15, 2546-2552
192. Gerl A, Clemm C, Lamerz R, Mann K, Wilmanns W (1993) Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease. Eur J Cancer 29A, 961-965
193. Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Nisselbaum J, Bajorin D, Bosl GJ (1994) Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 73, 2520-2526
194. de Wit R, Collette L, Sylvester R, de Mulder PH, Sleijfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Stoter G (1998) Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 78, 1350-1355
195. Zon RT, Nichols C, Einhorn LH (1998) Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 16, 1294-1297
173. Kuczyk M, Machtens S, Stief C, Jonas U (1999) Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (GCT). Int J Cancer 83, 852-855
196. Fossa SD, Borge L, Aas N, Johannessen NB, Stenwig AE, Kallhus O (1987)Treatment of advanced metastatic seminoma : experience in 55 cases. J Clin Oncol 5, 1071-1077
197. Herr HW, Bosl G (1987) Residual mass after chemotherapy for seminoma: changing concepts of management. J Urol 137, 1234-1235
198. Hofmockel G, Gruss A, Theiss M (1996) Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol Int 57, 38-42
199. Kamat MR, Kulkarni JN, Tongoankar HB, Ravi R (1992) Value of retroperitoneal lymph node dissection in advanced testicular seminoma. J Surg Oncol 51, 65-67
200. Loehrer PJ Sr, Birch R, Williams SD, Greco FA, Einhorn LH (1987) Chemotherapy of metastatic seminoma: The Southeastern Cancer Study Group experience. J Clin Oncol 5, 1212-1220
201. Motzer R, Bosl G, Heelan R, Fair W, Whitmore W, Sogani P, Herr H, Morse M (1987) Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 5, 1064-1070
202. Peckham MJ, Horwich A, Hendry WF (1985) Advanced seminoma treatment with cisplatinum based combination chemotherapy or carboplatin (JM8). Br J Cancer 52, 7-13
203. Duchesne GM, Stenning SP, Aass N, Mead GM, Fossa SD, Oliver RTD, Horwich A, Read G, Roberts IT, Rustin G, Cullen MH, Kaye SB, Harland SJ, Cook PA (1997) Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role. Eur J Cancer 33, 829-835
204. Bamberg M, Claßen J (1998) Stellenwert der Strahlentherapie von Residualtumoren nach Chemotherapie metastasierter Seminome. Strahlenther Onkol 174, 442-443
205. Puc H, Heelan R, Mazumdar M, Herr H, Sheinfeld J, Vlamis V, Bajorin DF, Bosl GJ, Mencel P, Motzer RJ (1996) Management of residual mass in advanced seminoma: results and recommendations from Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14, 454-460
206. Fossa SD, Ous S, Lien HH, Stenwig AE (1989) Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 141, 557-559
207. Toner GC, Panicek DM, Heelan RT, Geller NL, Lin SY, Bajorin D, Motzer RJ, Scher HJ, Herr HW, Morse MJ (1990): Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8, 1683-1694
208. Donohue JP, Rowland RG, Kopecky K, Steidle CP, Geier G, Ney KG, Einhorn L, Williams S, Loehrer P (1987): Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 137, 1176-1179
209. - Richie JP (1984) The surgical management of advanced abdominal disease. Semin Urol 2, 238-243
210. Stomper PC, Fung CY, Socinski MA, Jochelson MS, Garnick MB, Richie JP (1987) Detection of retroperitoneal metastases in early-stage nonseminomatous testicular cancer: analysis of different CT criteria. Am J Roentgenol 149, 1187-1190
211. Aprikian AG, Herr HW, Bajorin DF, Bosl GJ (1994) Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 74, 1329-1334
212. Herr HW (1997) Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Br J Urol 80, 653-657
213. Hendry WF, A´Hern RP, Hetherington JW, Peckham MJ, Dearnaley DP, Horwich A (1993) Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumors: prognostic value and therapeutic benefit. Br J Urol 71, 208-213
214. Wood DP, Herr HW, Heller G, Vlamis V, Sogani PC, Motzer RJ, Fair WR, Bosl GJ (1992) Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 148, 1812-1816
215. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP (1995) Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 153, 976-980
216. Hartmann JT, Schmoll H-J, Kuczyk MA, Candelaria M, Bokemeyer C (1997a) Postchemotherapy resections of residual masses from metastatic non-seminomatous germ cell tumors. Ann Oncol 8, 531-538
217. Rabbani F, Goldenberg SL, Gleave ME, Paterson RF, Murray N, Sullivan LD (1998) Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of the residual mass sufficient ? Br J Urol 81, 295-300
218. Tekgul S, Özen HA, Celebi I, Özgu I, Ergen A, Demircin M, Remzi D (1994) Postchemotherapeutic surgery for metastatic testicular germ cell tumors: results of extended primary chemotherapy and limited surgery. Urology 43, 349-354
219. Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, Schraffordt Koops H, Mulders PF, Messemer JE, Ney K, Donohue JP (1995) Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13, 1177-1187
220. Hartmann JT, Candelaria M, Kuczyk MA, Schmoll H-J, Bokemeyer C (1997b) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 33, 843-847
221. Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fossa SD, Horwich A, Jones WG, Newlands ES, Oliver RT, Stenwig AE. Wilkinson PM for the MRC Testicular Tumour Working Party (1998) Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 83, 1409-1419
222. Weinknecht S, Hartmann M, Weißbach L: Bei welchen markerpositiven Patienten mit Keimzelltumoren ist die Residualtumorresektion sinnvoll? (1998) Urologe A 37, 621-624
223. Cagini L, Nicholson AG, Horwich A, Goldstraw P, Pastorino U (1998) Thoracic metastasectomy for germ cell tumours: long term survival and prognostic factors. Ann Oncol 9, 1185-1191
224. Tiffany P, Morse MJ, Bosl G, Vaughan ED, Sogani PC, Herr HW, Whitmore WF (1986) Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cel tumors. Cancer 57, 978-983
225. Donohue JP (1989) The case for retroperitoneal lymphadenectomy after chemotherapy for selected patients with nonseminomatous tumours of the testis. In: Carlton CE (ed) Controversies in Urology. Year Book Publishers, Chicago, pp 225-229
226. Hendry WF, Barrett A, McElwain JJ, Wallace DM, Peckham MJ (1980) The role of surgery in the combined management of metastases from malignant teratomas of the testis. Br J Urol 52, 38-44
216. Hartmann JT, Schmoll H-J, Kuczyk MA, Candelaria M, Bokemeyer C (1997) Postchemotherapy resections of residual masses from metastatic non-seminomatous germ cell tumors. Ann Oncol 8, 531 - 538
221. Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fossa SD, Horwich A, Jones WG, Newlands ES, Oliver RT, Stenwig AE. Wilkinson PM for the MRC Testicular Tumour Working Party (1998) Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 83, 1409-1419
116. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJ, Cook PA (1999) Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80, 1392-1399
227. Miller KD, Loehrer PJ, Gonin R, Einhorn LH (1997) Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 15, 1427-1431
228. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W (1998) Salvagetherapie rezidivierter und refraktärer Hodentumoren. Onkologe 4, 541-546
therapy in germ cell tumors: response and survival. J Clin Oncol 15, 2559-2563
229. Loehrer PJ Sr, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16, 2500-2504
230. Kaye SB, Mead GM, Fossa S, Cullen M, deWit R, Bodrogi I, van Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck, Lallemand E, deMulder P (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16, 692-701
231. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W (1999) High-dose versus conventional-dose first-salvage treatment in nonseminoma: a matched-pair analysis. Proc Am Soc Clin Oncol 19, 326a (abstract 1255)
116. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJ, Cook PA (1999) Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80, 1392-1399
216. Hartmann JT, Schmoll H-J, Kuczyk MA, Candelaria M, Bokemeyer C (1997) Postchemotherapy resections of residual masses from metastatic non-seminomatous germ cell tumor. Ann Oncol 8, 531-538
222. Weinknecht S, Hartmann M, Weißbach L (1998) Bei welchen markerpositiven Patienten mit Keimzelltumoren ist die Residualtumorresektion sinnvoll? Urologe A 37, 621-624
232. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of testicular cancer. J Clin Oncol 13, 1170-1176
214. Wood DP, Herr HW, Heller G, Vlamis V, Sogani PC, Motzer RJ, Fair WR, Bosl GJ (1992) Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 148, 1812-1816
224. Tiffany P, Morse MJ, Bosl G, Vaughan ED, Sogani PC, Herr HW, Whitmore WF (1986) Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cel tumors. Cancer 57, 978-983
233. Cassidy J, Lewis CR, Kaye SB, Kirk D (1992) The changing role of surgery in metastatic non-seminomatous germ cell tumour. Br J Cancer 65, 127-129
234. Coogan CL, Foster RS, Rowland RG, Bihrle R, Smith ER Jr, Einhorn LH, Roth BJ, Donohue (1997) Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 50, 957-962
235. Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG (1994) Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 43, 74-80
236. Foster RS, Donohue JP(1998) Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? Urol Clin North Am 25, 479-484
237. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W (1997) Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8, 41-47
238. Kisbenedek L, Bodrogi I, Szeldeli P, Baki M, Tenke P, Horti J (1995) Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumors remaining marker positive after inductive chemotherapy. Int Urol Nephrol 27, 325-329
239. Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, Einhorn LH (1993) Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11, 324-329
240. Nichols C (1999) Treatment of recurrent germ cell tumors. Semin Surg Oncol 17, 268-274
241. Ravi R, Ong J, Oliver RT, Badenoch DF, Fowler CG, Hendry WF (1998) Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumors. Br J Urol 81, 884-888
242. Albers P, Dommer K, Müller, SC (1998) Hodentumoren – Todesfälle und Rezidive nach inadäquater Therapie. Urologe A 37, 625-628
243. Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, de Mulder PH, Neymark N, Lallemand E, Kaye (1999) Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborativ Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91, 839-846
244. Unger G, Wegener G, Günther B (1996) Hodentumoren in Niedersachsen und Bremen. Kassenärztliche Vereinigung Niedersachsen, Hannover
54. White PM, Howard GC, Best JJ, Wright AR (1997) The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours. Clin Radiol 52, 124-129
55. White PM, Adamson DJA, Howard GCW, Wright AR (1999) Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol 54, 207-211
242. Albers P, Dommer K, Müller, SC (1998) Hodentumoren – Todesfälle und Rezidive nach inadäquater Therapie. Urologe A 37, 625-628
243. Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, de Mulder PH, Neymark N, Lallemand E, Kaye (1999) Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborativ Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91, 839-846
244. Unger G, Wegener G, Günther B (1996) Hodentumoren in Niedersachsen und Bremen. Kassenärztliche Vereinigung Niedersachsen, Hannover
245. Wright AR, White PM (1999) Testicular cancer – who needs surveillance pelvic CT? Clin Radiol 44, 78
156. Sharir S, Foster RS, Jewett MAS, Sturgeon JFG, Moore M, Donohue JP (1996) Optimizing follow up for early stage nonseminomatous testicular cancer. J Urol 155, 327a EBM III/IV
246. Schölermann KH, Dettmann R, Hartmann M (1996) Die risikogesteuerte Hodentumornachsorge. Urologe A 35, 326-330 EBM III
247. Sharir S, Foster RS, Donohue JP, Jewett MA (1996) What is the appropriate follow up after treatment? Semin Urol Oncol 14, 45-35 EBM III/IV
248. Empfehlungen der ACS (American Cancer Society) (1996): Consultants: Einhorn LH, Bosl G in: Fischer DS (ed.): Follow-up of cancer: Testicular cancer. A handbook for physicians, 4th ed. Lippincott-Raven Publisher, Philadelphia New York, pp 68-69; 70-73 EBM IV
123. Warde P, Gospodarowicz MK, Panzarella T, Catton CN, Sturgeon JF, Moore M, Goodman P, Jewett MA (1995) Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 13, 2255-2262 EBM III
128. Warde P, Jewett M (1998) Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 25, 425-433 EBM III
138. Sternberg CN (1998) The management of stage I testis cancer. Urol Clin North Am 25, 435-449 EBM IA
249. Coleman JM, Coleman RE, Turner AR, Radstone CR, Champion AE (1998) The management and clinical course of testicular seminoma: 15 years‘ experience at a single institution. Clin Oncol (R Coll Radiol) 10, 237-241 EBM III
250. Miki T, Nonomura N, Saiki S, Kotake T (1998) Long-term results of adjuvant irradiation or surveillance in stage I testicular seminoma. Int J Urol 5, 357-360 EBM III
142. Bauman GS, Venkatesan VM, Ago CT, Radwan JS, Dar AR, Winquist EW (1998) Postoperative radiotherapy for stage I/II seminoma: results for 212 patients. Int J Radiat Oncol Biol Phys 42, 313-317 EBM III
149. Warde P, Gospodarowicz M, Panzarella T, Catton C, Sturgeon J, Moore M, Jewett M (1998) Management of stage II seminoma. J Clin Oncol 16, 290-294 EBM III
251. Morgan G, Leong T, Berg D (1997) Management of seminoma of the testis: recommandations based on treatment results. Aust NZ Surg 67, 15-20 EBM III
232. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of testicular cancer. J Clin Oncol 13, 1170-1176 EBM III
246. Schölermann KH, Dettmann R, Hartmann M (1996) Die risikogesteuerte Hodentumornachsorge. Urologe A 35, 326-330 EBM III
246. Schölermann KH, Dettmann R, Hartmann M (1996) Die risikogesteuerte Hodentumornachsorge. Urologe A 35, 326-330 EBM III
252. Gels ME, Hoekstra HJ, Sleijfer DT, Marrink J, de Bruijn HW, Molenaar WM, Freling NJ, Droste JH, Schaffordt Koops (1995) Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single center 10-years experience. J Clin Oncol 13, 1188-1194 EBM III
253. Sharir S, Jewett MA, Sturgeon JF, Moore M, Warde PR, Catton CN, Gospodarowicz MK (1999) Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol. J Urol 161, 472-476 EBM III
254. Thomas R, Dearnaley D, Nicholls J, Norman A, Sampson S, Horwich A (1996). An analysis of surveillance for stage I combined teratoma-seminoma of the testis. Br J Cancer 74, 59-62 EBM III
106. Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HAT, Bosl G (1998) Clinical stage I testis cancer: longterm outcome of patients on surveillance. J Urol 159, 855–858 EBM IIA
160. Pont J, Albrecht W, Postner G, Sellner F, Angel K, Höltl W (1996) Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14, 441-448 EBM IIB
252. Gels ME, Hoekstra HJ, Sleijfer DT, Marrink J, de Bruijn HW, Molenaar WM, Freling NJ, Droste JH, Schaffordt Koops (1995) Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single center 10-years experience. J Clin Oncol 13, 1188-1194 EBM III
253. Sharir S, Jewett MA, Sturgeon JF, Moore M, Warde PR, Catton CN, Gospodarowicz MK (1999) Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol. J Urol 161, 472-476 EBM III
237. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W (1997) Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8, 41-47 EBM III
255. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1995) Clinical stage B nonseminomatous germ cell testis cancer: the Indiana University experience (1965-1985) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31 A, 1599-1604 EBM III
256. Frohlich MW, Small EJ (1998) Stage II seminomatous testis cancer: the roles of primary and adjuvant chemotherapy. Urol Clin North Am 25, 451-459 EBM IA
257. Motzer RJ (1996) Adjuvant chemotherapy for stage II nonseminomatous testicular cancer: what is ist role? Sem Urol Oncol 14, 30-33 EBM IA
165. Donohue JP, Thornhill JA, Foster RS, Bihrle R, Rowland RG, Einhorn LH (1995) The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: The Indiana University experience (1965 to 1989). J Urol 153, 85-89 EBM III
258. Culine S, Theodore C, Court BH, Perrin JL, Droz JP (1997) Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis. Br J Urol 79, 258-262 EBM III
259. Horwich A, Norman A, Fisher C, Hendry WF, Nicholls J, Dearnaley DP (1994) Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. J Urol 151, 72-78 EBM III
260. Horwich A, Stenning S (1994) Initial chemotherapy for stage II testicular nonseminoma. World J Urol 12, 148-150 EBM III
116. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJ, Cook PA (1999) Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80, 1392-1399 EBM III
237. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W (1997) Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8, 41-47 EBM III
261. Donohue JP, Foster RS, Little JS, Loehrer PJ, Einhorn LE (1996) Biology of metastases and its clinical implications: testicular germ-cell tumors. World J Urol 14, 197-203 EBM III
262. Ravi R, Oliver RTD, Ong J, Badenoch DF, Fowler CG, Paris AMI, Hendry WF (1997) A single-center observational study of surgery and late malignant events after chemotherapy for germ cell cancer. Br J Urol 80, 647-652 EBM III
232. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of testicular cancer. J Clin Oncol 13, 1170-1176 EBM IV
237. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W (1997) Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8, 41-47 EBM III
263. Sonneveld D, Sleijfer D, Schraffordt Koops H, Keemers-Gels M, Molenaar W, Hoekstra H (1998) Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors. Cancer 82, 1343-1351 EBM III
55. White PM, Adamson DJA, Howard GCW, Wright AR (1999) Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol 54, 207-211 EBM III
245. Wright AR, White PM (1999) Testicular cancer – who needs surveillance pelvic CT? Clin Radiol 44, 78 EBM IV
136. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF, Boice JD (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89, 1429-1439
137. Travis L, Andersson M, Holowarty E, Van Leeuwen F, Bergfeldt K, Lynch C, Kohler B, Wiklund T, Curtis R, Storm H, Clarke E, Hall P, Pukkala E, Sturgeon J, Boice Jr, J, Gospodarowicz M, Sovall M, Gilbert E (1999) Risk of Leukemia following radiotherapy and chemotherapy for testicular cancer. Proc Am Soc Clin Onc 18, 308a (abstract 1185)
181. Bokemeyer C, Schmoll H-J (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11, 1703-1709
